Jill Rollet is the Executive Editor at Endocrine Today. She specializes in medicine and healthcare, with a focus on medical specialties such as immunology, palliative care, remote healthcare, endocrinology, and gene therapy. Jill's work has been featured in Healio.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jill Rollet's coverage primarily focuses on healthcare, scientific developments, and health & wellbeing topics. She frequently cites data and provides expert commentary in her articles.
Given the nature of Jill's coverage, she is likely to be interested in pitches that offer access to credible experts who can provide insights into the latest scientific or medical research within women’s health, reproductive health, diabetes, menopause and related areas. Pitches should emphasize providing exclusive access to new data or studies as well as opportunities for expert commentary on relevant healthcare issues.
As there is no specific geographic focus mentioned for Jill Rollet's coverage area,pitches with international perspectives would likely be of interest given the global relevance of healthcare topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Samir M. Parikh, Richard Smith, Jill Rollet
American Society of Nephrology members visited lawmakers in Washington D.C. on March 10 to advocate during their Hill Day for increasing visibility and research for kidney care.
By: Richard Smith, Jill Rollet, Kirk Campbell
Kidney disease is greatly underdiagnosed and undertreated in the United States, but recent initiatives aim to change that, according to Kirk Campbell, MD, president of the National Kidney Foundation.
By: Jill Rollet
NEW ORLEANS — Patients with decompensated heart failure and kidney disease may have care expectations and understanding of prognoses that are “misaligned” with outcomes, according to researchers.
NEW ORLEANS — Mentoring from other patients may contribute to faster recovery time for patients undergoing hemodialysis, according to study data presented at the National Kidney Foundation Spring Clinical Meetings. “Dialysis is a demanding treatment,” Tiffany Veinot, MLS, PhD, the Joan C. Durrance Collegiate Professor of Information at the University of Michigan School of Information, told
By: Lilia Cervantes, Lucas Laboy, Jill Rollet
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Erik Swain, Richard Smith, Jill Rollet
Editor's Note: After the June issue of Healio | Endocrine Today went to press, a U.S. district judge voided the H-1B visa fee discussed in this article.
By: Richard Smith, Jill Rollet
In December 2021, the FDA approved the first therapy indicated to treat primary immunoglobulin A nephropathy.
PHILADELPHIA — With combination therapies and multiple treatment options available for patients, nephrology is in a “therapeutic revolution,” according to a speaker at the Heart in Diabetes CME Conference.
By: Jill Rollet, Lucas Laboy
Patients receiving short daily home dialysis reported better habitual physical activity rates and other quality of life improvements vs. patients receiving in-center hemodialysis, according to study data published in Kidney360
By: Lucas Laboy, Jill Rollet
Among adults with diabetes undergoing kidney biopsy, operator experience and needle gauge selection were associated with adverse event risks rather than diabetes itself, according to study data.
